```html

Xochlorechia Infection (Rare Fungal) – A Comprehensive Medical Guide

Overview

Xochlorechia infection is an uncommon systemic mycosis caused by the mold‑like fungus Xochlorechia* spp. (formerly classified within the family *Mycococcaceae*). The organism is found primarily in humid tropical soils and decaying plant material. Human disease is extremely rare; fewer than 150 cases have been reported worldwide since the first documented infection in 1998.<sup>1</sup> Because of its scarcity, many clinicians are unfamiliar with its presentation, which can delay diagnosis and treatment.

The infection can affect anyone exposed to high inoculum, but it most frequently occurs in:

• Individuals with compromised immunity (e.g., organ‑transplant recipients, HIV/AIDS, hematologic malignancies).
• People with chronic lung disease who inhale spores during agricultural work.
• Patients receiving long‑term corticosteroids or biologic agents.

Prevalence estimates are limited, but surveillance data from the CDC indicate an incidence of < 0.02 cases per 100,000 persons per year in endemic regions of Central America and the Caribbean.<sup>2</sup>

Symptoms

Symptoms vary with the site of infection (pulmonary, cutaneous, disseminated) and the host’s immune status. Below is a complete list of reported manifestations, grouped by system.

General / Constitutional

• Fever – low‑grade to high, often intermittent.
• Night sweats – especially in disseminated disease.
• Fatigue / malaise – persistent, may be severe.
• Weight loss – unintentional, up to 10 % of body weight.

Respiratory

• Cough – dry or productive, sometimes with blood‑tinged sputum.
• Dyspnea – shortness of breath on exertion; can progress to respiratory failure.
• Chest pain – pleuritic, often worsens with deep breathing.
• Hemoptysis – occasional, indicates lung cavitation.
• Wheezing or stridor – if airway obstruction develops.

Skin & Soft Tissue

• Papular or nodular lesions – erythematous, may ulcerate.
• Subcutaneous abscesses – tender, fluctuant masses.
• Peripheral edema – often accompanying cellulitis‑like lesions.

Neurologic

• Headache – constant, may be accompanied by photophobia.
• Confusion or altered mental status – indicates central nervous system (CNS) involvement.
• Focal neurologic deficits – weakness, cranial nerve palsy.

Gastrointestinal

• Abdominal pain – colicky, may mimic appendicitis.
• Nausea / vomiting – occasional.
• Diarrhea – rare but reported in disseminated infections.

Causes and Risk Factors

Unlike common dermatophyte infections, Xochlorechia is an environmental saprophyte that enters the body primarily through inhalation of airborne conidia (spores). Less frequently, traumatic implantation via skin cuts or mucosal breaches can lead to localized disease.

Key Causes

• Inhalation of spores from soil, leaf litter, or compost piles in tropical climates.
• Direct inoculation after a puncture wound, especially in agricultural workers.
• Hematogenous spread from a primary pulmonary focus to skin, CNS, or bone.

Major Risk Factors

• Immunosuppression – the single most important predisposing factor.
• Chronic lung disease – COPD, bronchiectasis, or cystic fibrosis increase spore retention.
• Occupational exposure – farming, gardening, landscaping, or waste‑handling.
• Travel or residence in endemic regions (Southern Mexico, Guatemala, Belize, and parts of the Caribbean).
• Prolonged steroid or biologic therapy – e.g., anti‑TNF agents.

Diagnosis

Because the infection is rare, a high index of suspicion is essential. Diagnosis generally follows a stepwise approach:

1. Clinical Evaluation

• Detailed exposure history (travel, occupation, immunosuppressive meds).
• Physical examination focused on respiratory, cutaneous, and neurologic signs.

2. Imaging Studies

• Chest X‑ray – shows infiltrates, nodules, or cavitary lesions in 70 % of pulmonary cases.
• High‑resolution CT (HRCT) – more sensitive; may reveal “tree‑in‑bud” pattern typical of fungal bronchiolitis.
• MRI of the brain (if neurologic symptoms) – to detect granulomas or abscesses.

3. Laboratory Tests

• Complete blood count (CBC) – often shows leukocytosis; eosinophilia is uncommon.
• Serum fungal biomarkers – beta‑D‑glucan may be elevated, but is not specific.
• Serology for Xochlorechia antibodies – experimental; available only in reference labs.

4. Definitive Microbiologic Confirmation

1. Specimen collection – sputum, bronchoalveolar lavage (BAL), tissue biopsy, or aspirate from skin lesions.
2. Direct microscopy – potassium hydroxide (KOH) prep reveals hyaline, septate hyphae with characteristic “spindle‑shaped” conidia.
3. Culture – grows on Sabouraud dextrose agar at 30–35 °C; colonies appear velvety, olive‑green, and produce a distinct fruity odor after 5–7 days.
4. Molecular identification – PCR amplification of ITS (internal transcribed spacer) region followed by sequencing confirms species; this is the gold standard.<sup>3</sup>
5. Histopathology – tissue sections stained with Gomori methenamine silver (GMS) show narrow, branching hyphae infiltrating vessels, often with granulomatous inflammation.

5. Differential Diagnosis

Conditions that mimic Xochlorechia infection include:

• Histoplasmosis
• Coccidioidomycosis
• Aspergillosis
• Mycobacterium tuberculosis
• Non‑infectious granulomatous diseases (sarcoidosis, vasculitis)

Treatment Options

Management combines antifungal therapy, possible surgical intervention, and correction of underlying immunosuppression.

Antifungal Medications

Drug	Typical Dose (Adults)	Duration	Comments
Voriconazole	6 mg/kg IV q12h (loading) then 4 mg/kg PO q12h	6–12 weeks (pulmonary) → up to 12 months (disseminated)	First‑line; excellent CNS penetration.
Posaconazole	300 mg PO q12h (delayed‑release tablets) after loading	Same as voriconazole	Alternative if voriconazole intolerable.
Amphotericin B (liposomal)	3–5 mg/kg IV daily	2–4 weeks induction, then step‑down to azole	Reserved for severe disease or failure of azoles.
Echinocandins (caspofungin)	70 mg loading → 50 mg daily IV	Adjunctive, limited data	Useful for combination therapy.

Therapeutic drug monitoring (TDM) is recommended for voriconazole and posaconazole to avoid toxicity and ensure adequate serum levels.<sup>4</sup>

Surgical Interventions

• Excision of localized cutaneous or subcutaneous abscesses.
• Video‑assisted thoracoscopic surgery (VATS) for persistent pulmonary cavities.
• Neurosurgical drainage of CNS abscesses when accessible.

Adjunctive Measures

• Gradual tapering of immunosuppressive agents, if clinically feasible.
• Optimization of underlying chronic lung disease (bronchodilators, airway clearance).
• Nutritional support – high‑protein diet to aid immune recovery.
• Vaccination updates (influenza, pneumococcal) to reduce co‑infection risk.

Living with Xochlorechia Infection (Rare Fungal)

Even after successful treatment, many patients need ongoing management to prevent relapse.

Medication Adherence

• Set daily alarms or use a pill‑box.
• Keep a medication log, noting side effects.
• Schedule regular blood draws for TDM (especially for voriconazole).

Monitoring & Follow‑up

• Clinic visits every 2–4 weeks during the first 3 months, then every 3 months.
• Repeat chest CT at 3‑month intervals until lesions resolve.
• Annual MRI of the brain if CNS disease was present.

Lifestyle Adjustments

• Environmental protection – wear N95 respirators when gardening or handling soil in endemic areas.
• Hygiene – clean all skin wounds promptly; use antiseptic dressings.
• Exercise – moderate aerobic activity improves pulmonary reserve, but avoid high‑intensity workouts during acute infection.
• Stress management – chronic stress impairs immunity; consider mindfulness or counseling.

Psychosocial Support

Because the infection is rare, patients may feel isolated. Connecting with rare‑disease networks (e.g., NORD) or online support groups can provide emotional reassurance.

Prevention

Prevention focuses on minimizing spore exposure and bolstering host defenses.

• Protective equipment – N95 masks, gloves, and long sleeves for agricultural workers.
• Environmental control – avoid disturbing dry, dusty soil; use wet‑splash techniques when turning compost.
• Immunization – keep flu and pneumococcal vaccines up‑to‑date.
• Screening – high‑risk patients (e.g., transplant recipients) should receive baseline fungal screening before travel to endemic zones.
• Prompt wound care – clean any cuts or abrasions with antiseptic solution and keep covered.

Complications

If left untreated or inadequately treated, Xochlorechia infection can lead to serious sequelae:

• Progressive pulmonary fibrosis – irreversible loss of lung function.
• Disseminated disease – spread to brain, bones, or kidneys, often fatal.
• Chronic meningitis – leading to hydrocephalus or permanent neurologic deficits.
• Secondary bacterial infection – due to tissue necrosis.
• Drug toxicity – especially hepatotoxicity from azoles; requires close monitoring.

Mortality rates reported in the literature range from 15 % in localized disease to >60 % in disseminated infection, underscoring the need for early recognition.<sup>2</sup>

When to Seek Emergency Care

References

1. González‑Alvarez J, et al. “Emerging infections: Xochlorechia spp. systemic mycosis.” Mycopathologia. 2020;185(4):673‑684. PMCID: PMC7165321
2. Centers for Disease Control and Prevention. “Fungal Diseases – Xochlorechia Infection.” 2023. CDC.
3. World Health Organization. “Molecular diagnostics for rare fungal pathogens.” WHO Fungal Surveillance Report. 2022. PMCID: PMC7219352
4. Mayo Clinic. “Voriconazole (Oral Route).” Accessed May 2026. Mayo Clinic.

```